We are live on ! Find out more
CLYM

Climb Bio

71 hedge funds and large institutions have $278M invested in Climb Bio in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 28 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

343% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 7

300% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 7

51% more funds holding

Funds holding: 4771 (+24)

22% less capital invested

Capital invested by funds: $355M → $278M (-$76.7M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

86.25% less ownership

Funds ownership: 167.76%81.52% (-86%)

Holders
71
Holders Change
+24
Holders Change %
+51.06%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
31
Increased
28
Reduced
7
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PAMP
76
Polar Asset Management Partners
Ontario, Canada
-$76.7K -10,781 Closed
TSS
77
Two Sigma Securities
New York
-$75.5K -10,619 Closed
Carson Wealth (CWM LLC)
78
Carson Wealth (CWM LLC)
Nebraska
+$141 +20 New

CLYM Hedge Fund Activity: Q3 2024 in Review

71 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2024, worth a combined $278M — down 22% from $355M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new CLYM positions and 7 closed out — a net gain of 24 holders — while 28 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Deep Track Capital, cutting an estimated $12.3M.

  • 71 institutional investors held Climb Bio (CLYM) as of Q3 2024, up from 47 in Q2 2024.
  • Funds reported $278M of Climb Bio stock for Q3 2024, down 22% quarter-over-quarter.
  • 31 funds opened new Climb Bio positions in Q3 2024 and 7 closed out, a net change of +24 holders.
  • The largest Climb Bio buyer in Q3 2024 was BlackRock, an estimated $10.5M added.
  • The largest Climb Bio seller in Q3 2024 was Deep Track Capital, an estimated $12.3M sold.

Based on aggregated 13F filings for Q3 2024.